An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the ...

Novo Nordisk (NVO) faces a 6% premarket drop after clinical trial results for its obesity drug CagriSema fell below ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

Subcutaneous emphysema is the medical term for air becoming trapped in tissues beneath the skin. It is rare, but may occur as a result of trauma, injury, infection, or certain medical procedures.

The following is a summary of “Effect of spesolimab on sustained disease control in patients with generalized pustular ...

H.C. Wainwright says Novo Nordisk’s REDEFINE-2 results reinforce Viking Therapeutics’ VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema a ...